Verrica Pharmaceuticals Inc.

Symbol: VRCA

NASDAQ

7.07

USD

Market price today

  • -4.9240

    P/E Ratio

  • 0.0381

    PEG Ratio

  • 299.90M

    MRK Cap

  • 0.00%

    DIV Yield

Verrica Pharmaceuticals Inc. (VRCA) Stock Price & Analysis

Shares Outstanding

42.42M

Gross Profit Margin

0.86%

Operating Profit Margin

-12.34%

Net Profit Margin

-12.98%

Return on Assets

-0.81%

Return on Equity

-1.46%

Return on Capital Employed

-0.98%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Ted White
Full-time employees:100
City:West Chester
Address:44 West Gay Street
IPO:2018-06-15
CIK:0001660334

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

General Outlook

In simple terms, Verrica Pharmaceuticals Inc. has 42.419 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.858% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -12.338%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -12.977%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.815% return, is a testament to Verrica Pharmaceuticals Inc.'s adeptness in optimizing resource deployment. Verrica Pharmaceuticals Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.459%. Furthermore, the proficiency of Verrica Pharmaceuticals Inc. in capital utilization is underscored by a remarkable -0.979% return on capital employed.

Stock Prices

Verrica Pharmaceuticals Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $6.03, while its low point bottomed out at $5.58. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Verrica Pharmaceuticals Inc.'s stock market.

Liquidity Ratios

Analyzing VRCA liquidity ratios reveals its financial health of the firm. The current ratio of 455.42% gauges short-term asset coverage for liabilities. The quick ratio (434.46%) assesses immediate liquidity, while the cash ratio (408.52%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio455.42%
Quick Ratio434.46%
Cash Ratio408.52%

Profitability Ratios

VRCA profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -1307.47% underscores its earnings before tax deductions. The net income per EBT, 99.25%, and the EBT per EBIT, 105.97%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -1233.82%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-1307.47%
Net Income per EBT99.25%
EBT per EBIT105.97%
EBIT per Revenue-1233.82%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.55, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations. Meanwhile, a 4 cash conversion cycle and 116.03% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding434
Days of Inventory Outstanding511
Operating Cycle825.92
Days of Payables Outstanding1233
Cash Conversion Cycle-407
Receivables Turnover1.16
Payables Turnover0.30
Inventory Turnover0.71
Fixed Asset Turnover1.42
Asset Turnover0.06

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.84, and free cash flow per share, -0.85, depict cash generation on a per-share basis. The cash per share value, 1.50, showcases liquidity position. Lastly, the operating cash flow sales ratio, -7.57, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.84
Free Cash Flow per Share-0.85
Cash per Share1.50
Operating Cash Flow Sales Ratio-7.57
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-0.89
Short Term Coverage Ratio-55.43
Capital Expenditure Coverage Ratio-107.19
Dividend Paid and Capex Coverage Ratio-107.19

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 53.40%, highlights its total liabilities relative to assets. With a debt-equity ratio of 2.20, we discern the balance between debt and equity financing. The long-term debt to capitalization, 68.45%, and total debt to capitalization, 68.80%, ratios shed light on its capital structure. An interest coverage of -427.17 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio53.40%
Debt Equity Ratio2.20
Long Term Debt to Capitalization68.45%
Total Debt to Capitalization68.80%
Interest Coverage-427.17
Cash Flow to Debt Ratio-0.89
Company Equity Multiplier4.13

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.11, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.48, reflects the portion of profit attributed to each share. The book value per share, 0.44, represents the net asset value distributed per share, while the tangible book value per share, 0.44, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.11
Net Income Per Share-1.48
Book Value Per Share0.44
Tangible Book Value Per Share0.44
Shareholders Equity Per Share0.44
Interest Debt Per Share1.05
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -43.27%, indicates top-line expansion, while the gross profit growth, -52.33%, reveals profitability trends. EBIT growth, -196.87%, and operating income growth, -196.87%, offer insights into operational profitability progression. The net income growth, -142.05%, showcases bottom-line expansion, and the EPS growth, -82.72%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-43.27%
Gross Profit Growth-52.33%
EBIT Growth-196.87%
Operating Income Growth-196.87%
Net Income Growth-142.05%
EPS Growth-82.72%
EPS Diluted Growth-82.72%
Weighted Average Shares Growth32.72%
Weighted Average Shares Diluted Growth32.72%
Operating Cash Flow Growth-106.85%
Free Cash Flow Growth-105.46%
10-Year Operating CF Growth per Share-953.40%
5-Year Operating CF Growth per Share30.21%
3-Year Operating CF Growth per Share29.60%
10-Year Net Income Growth per Share-1440.59%
5-Year Net Income Growth per Share-4.92%
3-Year Net Income Growth per Share18.83%
10-Year Shareholders Equity Growth per Share426.35%
5-Year Shareholders Equity Growth per Share-92.85%
3-Year Shareholders Equity Growth per Share-66.97%
Receivables Growth806.78%
Inventory Growth309.86%
Asset Growth82.46%
Book Value per Share Growth-62.80%
Debt Growth2882.31%
R&D Expense Growth66.38%
SGA Expenses Growth169.39%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 307,869,741.32, captures the company's total value, considering both debt and equity. Income quality, 0.58, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value307,869,741.32
Income Quality0.58
Research and Development to Revenue396.08%
Capex to Operating Cash Flow0.94%
Capex to Revenue-7.06%
Capex to Depreciation-43.30%
Stock-Based Compensation to Revenue280.56%
Graham Number3.81
Return on Tangible Assets-82.10%
Graham Net Net0.25
Working Capital60,506,000
Tangible Asset Value19,763,000
Net Current Asset Value15,696,000
Invested Capital2
Average Receivables2,451,500
Average Payables1,485,500
Average Inventory267,500
Days Sales Outstanding315
Days Payables Outstanding773
Days of Inventory On Hand320
ROIC-96.86%
ROE-3.39%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 16.57, and the price to book ratio, 16.57, reflect the market's valuation relative to the company's book value. The price to sales ratio, 58.53, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -7.66, and price to operating cash flows, -8.44, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio16.57
Price to Book Ratio16.57
Price to Sales Ratio58.53
Price Cash Flow Ratio-8.44
Price Earnings to Growth Ratio0.04
Enterprise Value Multiple-5.26
Price Fair Value16.57
Price to Operating Cash Flow Ratio-8.44
Price to Free Cash Flows Ratio-7.66
Price to Tangible Book Ratio16.79
Enterprise Value to Sales60.08
Enterprise Value Over EBITDA-4.93
EV to Operating Cash Flow-7.98
Earnings Yield-20.18%
Free Cash Flow Yield-11.73%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Verrica Pharmaceuticals Inc. (VRCA) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -4.924 in 2024.

What is the ticker symbol of Verrica Pharmaceuticals Inc. stock?

The ticker symbol of Verrica Pharmaceuticals Inc. stock is VRCA.

What is company IPO date?

IPO date of Verrica Pharmaceuticals Inc. is 2018-06-15.

What is company current share price?

Current share price is 7.070 USD.

What is stock market cap today?

The market cap of stock today is 299899502.000.

What is PEG ratio in 2024?

The current 0.038 is 0.038 in 2024.

What is the number of employees in 2024?

In 2024 the company has 100.